Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing

Explore how Oxford Nanopore direct DNA sequencing revolutionizes tumor methylation profiling in this comprehensive webinar featuring two cutting-edge presentations on cancer genomics. Learn about breakthrough approaches that enable real-time, comprehensive methylation analysis without bisulfite conversion, enzymatic treatment, or PCR amplification, delivering integrated insights into both genetic and epigenetic variations from tumor DNA samples. Discover the Acute Leukemia Methylome Atlas through Dr. Francisco Marchi's presentation, which showcases a harmonized dataset of over 3,000 leukemia samples and demonstrates how long-read nanopore sequencing combined with machine learning algorithms enables accurate AML subtype prediction and five-year survival modeling. Understand the clinical potential of rapid, cost-effective methylation-based diagnostics for blood cancers and how this technology is advancing precision medicine in hematologic malignancies. Examine Dr. Skarphedinn Halldorsson's work on nanopore whole-genome sequencing applications for comprehensive molecular profiling of central nervous system tumors. Gain insights into how this streamlined approach provides complete detection of diagnostically and therapeutically relevant alterations while enabling retrospective reclassification without additional testing, potentially replacing current genomic methods in molecular neuropathology with superior completeness, cost-effectiveness, and speed. Master the technical advantages of Oxford Nanopore's direct DNA sequencing technology and its transformative impact on tumor classification and clinical decision-making processes. Understand how this innovative approach is advancing precision oncology through enhanced speed, scalability, and analytical completeness, offering faster and more comprehensive insights from tumor samples than traditional methylation profiling methods.